Amicus's shares are now up by a whopping 178% so far this year, thanks to the successful commercial launch of Galafold in multiple ex-U.S. territories where the …
If we click on the stock ticker in the ‘My Holdings’ page ... Also on the horizon is expected biosimilar competition for Humalog (from Sanofi’s Admelog in 2019). …
Register now to create your own custom streaming stock watchlist. NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes. All other quotes are delayed by at least 15 minutes unless otherwise stated.
French drugmaker Sanofi in November agreed to co-develop and co-commercialize fitusiran with Alnylam in the United States, Canada and Western Europe. Alnylam also said on Thursday it would move forward a trial of its experimental …
CNBC11d
He wasn’t great in a season-opening win against Western Michigan … Read …
Paris, France - September 7, 2017 - Sanofi alliance partner Alnylam Pharmaceuticals today provided an update on the clinical development program for fitusiran, an investigational RNAi therapeutic in development for the treatment of …
The firm has a Buy rating on Sanofi and a $55 price target ... namely Lantus for diabetes and Plavix for the prevention of blood clot. Despite the floundering stock
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs. Its newest insulin product, Toujeo, just got approved by regulators for sale in the U.S., and …